Difference between revisions of "Electrodesiccation and curettage"
Jump to navigation
Jump to search
(+SO) |
(+another SO) |
||
| Line 17: | Line 17: | ||
Skin, Right Shoulder, Biopsy with Curettage and Electrodesiccation (CED): | Skin, Right Shoulder, Biopsy with Curettage and Electrodesiccation (CED): | ||
- BASAL CELL CARCINOMA, margin status assessed clinically during CED. | - BASAL CELL CARCINOMA, margin status assessed clinically during CED. | ||
</pre> | |||
<pre> | |||
Right Upper Lip, Biopsy with Curettage and Electrodesiccation (C+E): | |||
- INVASIVE SQUAMOUS CELL CARCINOMA (well-differentiated), margin status assessed clinically during C+E. | |||
</pre> | </pre> | ||
Revision as of 22:02, 27 February 2023
Electrodesiccation and curettage, abbreviated EDC and E+C, is a procedure in which:
- The lesion is cut-off (sent to pathology).
- The surgical site is cauterized using electricity (electrodesiccation).
- The electrodesiccated tissue is scrapped off (curettage).
General
- EDCs are typically done by family physicians and dermatologists for non-melanoma skin cancers.[1]
- The practise is not without controversy.[1][2]
Limitations of the technique are:
- The margin status is assessed clinically.
- The pathologist cannot comment on whether the margin is clear or the surgical clearance.
- The size of the lesion is usually impossible to determine on pathology.
Sign out
Skin, Right Shoulder, Biopsy with Curettage and Electrodesiccation (CED): - BASAL CELL CARCINOMA, margin status assessed clinically during CED.
Right Upper Lip, Biopsy with Curettage and Electrodesiccation (C+E): - INVASIVE SQUAMOUS CELL CARCINOMA (well-differentiated), margin status assessed clinically during C+E.
References
- ↑ 1.0 1.1 Goldman, G. (Jul 2002). "The current status of curettage and electrodesiccation.". Dermatol Clin 20 (3): 569-78, ix. PMID 12170889.
- ↑ Reschly, MJ.; Shenefelt, PD. (Jul 2010). "Controversies in skin surgery: electrodessication and curettage versus excision for low-risk, small, well-differentiated squamous cell carcinomas.". J Drugs Dermatol 9 (7): 773-6. PMID 20677531.